Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Sep;48(3):245-8.
doi: 10.1016/S1028-4559(09)60297-7.

Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection

Dehghani Firouzabadi Razieh  1 , Ayazi Rozbahani Maryam, Tabibnejad Nasim
Affiliations
Free article
Randomized Controlled Trial

Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection

Dehghani Firouzabadi Razieh et al. Taiwan J Obstet Gynecol. 2009 Sep.
Free article

Abstract

Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome.

Materials and methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes.

Results: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.

Conclusion: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.

PubMed Disclaimer

Publication types

LinkOut - more resources